StudyFinder

MT2015-25: Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Recruiting

The primary purpose of this study is to gain information, especially disease free outcomes, using the tandem approach as compared to the historical information of using a single transplant. The data will be analyzed for transplant “milestones” such as time to blood count recovery and how patients are doing at 3 months and 1 year after the treatment. Participation in this study will not alter treatment or medical care. All information for this study will be collected from medical records.

I'm interested

Male or Female
Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• less than 30 years old when diagnosis of neuroblastoma is made
• no uncontrolled infection
• recovered from acute toxicities of last cycle of induction chemotherapy
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Biological: Autologous Stem Cell Infusion, Drug: Carboplatin, Drug: Cyclophosphamide, Drug: Etoposide, Biological: Granulocyte colony stimulating factor, Drug: Melphalan, Drug: Thiotepa

Cancer

Neuroblastoma

Holly Franceen - hfrancee@umn.edu
Ashish Gupta
PHASE2
1601M82901
See this study on ClinicalTrials.gov

Back